单心室先天性心脏病患者Fontan手术中吸入一氧化氮的心脏保护与抗炎效果:一项前瞻性随机研究
该前瞻性随机研究纳入115例单心室先天性心脏病行Fontan手术患者,随机分为Fontan-NO组(n=48)与Fontan组(n=49),18例被排除;Fontan-NO组在体外循环期间向氧合器直接吸入NO。主要终点为术后呼吸支持时间,Fontan-NO组中位9.3 h(7.0; 13,2)vs Fontan组13.9 h(3.7; 18.5),绝对差4.6 h[95%CI -30.9至12.3;p=0.03]。Fontan-NO组ICU时间更短(p=0.04),停体外循环后、术后4 h及8 h肺动脉压力更低(p=0.04、p=0.03、p=0.03),停体外循环后乳酸(p=0.04)与葡萄糖(p=0.02)更低,儿茶酚胺指数更低(p=0.042),并出现IL-10升高及IL-6、IL-8、IL-1β、五聚素、MMP-8、肌钙蛋白I、CK-MB、胰岛素降低。作者认为体外循环期间向氧合器吸入NO可改善短期临床结局。
要点
- Fontan-NO组术后呼吸支持时间中位9.3 h(7.0; 13,2)vs Fontan组13.9 h(3.7; 18.5),绝对差4.6 h[95%CI -30.9至12.3;p=0.03]。
- Fontan-NO组ICU时间更短(p=0.04),停体外循环后、术后4 h及8 h肺动脉压力更低(p=0.04、p=0.03、p=0.03)。
- Fontan-NO组停体外循环后乳酸(p=0.04)与葡萄糖(p=0.02)更低,儿茶酚胺指数更低(p=0.042)。
- Fontan-NO组IL-10更高,IL-6、IL-8、IL-1β、五聚素、MMP-8、肌钙蛋白I、CK-MB及胰岛素更低。
- 作者认为体外循环期间向氧合器吸入NO可缩短插管时间与ICU时间,减轻炎症反应、改善心肌与肺保护并减少代谢应激。
适用人群与场景
- 单心室先天性心脏病行Fontan手术并接受体外循环的患者,年龄等纳入细节原文未报告。
处置流程与药物剂量
- Fontan-NO组在体外循环期间将NO直接吸入氧合器;NO浓度、剂量与疗程原文未报告。
研究设计与关键结果
- 前瞻性随机研究,115例随机分为Fontan-NO组(n=48)与Fontan组(n=49),18例被排除。
- 主要终点术后呼吸支持时间:Fontan-NO组中位9.3 h(7.0; 13,2)vs Fontan组13.9 h(3.7; 18.5),绝对差4.6 h[95%CI -30.9至12.3;p=0.03]。
- Fontan-NO组ICU时间更短(p=0.04)。
- Fontan-NO组停体外循环后(p=0.04)、术后4 h(p=0.03)及8 h(p=0.03)肺动脉压力更低。
- Fontan-NO组停体外循环后乳酸(p=0.04)与葡萄糖(p=0.02)更低,儿茶酚胺指数更低(p=0.042)。
- Fontan-NO组IL-10更高,IL-6、IL-8、IL-1β、五聚素、MMP-8、肌钙蛋白I、CK-MB及胰岛素更低。
证据类型、等级与局限
- 证据类型:前瞻性随机研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为体外循环期间向氧合器吸入NO可改善单心室行Fontan手术患者的短期临床结局,缩短插管时间与ICU时间,减轻炎症反应、改善心肌与肺保护并减少代谢应激。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Fontan surgery with cardiopulmonary bypass (CPB) causes tremendous systemic stress and inflammatory responses, affecting postoperative organ function, morbidity, and mortality. Although this reaction triggers partially protective anti-inflammatory responses, it is harmful in patients with single ventricle congenital heart defects. Despite decades of research, an effective anti-inflammatory and stress defense strategy is lacking. This study investigated the influence of inhaled nitric oxide (NO) during CPB on early clinical results, including the duration of postoperative respiratory support as a primary outcome and a panel of laboratory analytes.
METHODS: In this study, 115 patients were randomized to the Fontan-NO group (n = 48) and the Fontan group (n = 49). Eighteen patients were excluded from the study. The Fontan-NO group received NO inhaled directly into the oxygenator during CPB. Clinical data were collected, and blood samples were drawn for analysis at repeated intervals. Multiplex assays were used to analyze a proteome profile of molecules involved in stress response, inflammation, metabolic reactions, as well as heart and lung protection.
RESULTS: Fontan-NO patients had significantly shorter respiratory support time with a median of 9.3 h (7.0; 13,2) vs 13.9 h (3.7; 18.5) by the absolute difference of 4.6 h [95% confidence interval, - 30.9 to 12.3; (p = 0.03)]. In addition, they have a shorter time in intensive care (p = 0.04) and lower pulmonary artery pressure after CPB discontinuation (p = 0.04), 4 h (p = 0.03) and 8 h (p = 0.03) after surgery. Fontan-NO patients also had a lower concentration of lactates (p = 0.04) and glucose after separation from CPB (p = 0.02) and lower catecholamine index (p = 0.042). Plasma factors analysis has shown a significantly higher concentration of interleukin-10, and a lower concentration of interleukin-6, interleukin-8, interleukin-1β, pentraxin, matrix metalloproteinase-8, troponin-I, creatine kinase myocardial band (CK-MB), and insulin in Fontan-NO group.
CONCLUSIONS: NO inhaled into the oxygenator during CPB can improve short-term clinical outcomes. It shortens intubation time and intensive care time. It reduces inflammatory response, improves myocardial and lung protection, and diminishes metabolic stress in patients with a single ventricle undergoing Fontan surgery.
TRIAL REGISTRATION NUMBER: The trial was preregistered, supervised, and supported by The Polish National Science Center ( NCN/01/B/NZ5/04246 ).
参考来源
- Kolcz J, Karnas E, Madeja Z, et al. The cardioprotective and anti-inflammatory effect of inhaled nitric oxide during Fontan surgery in patients with single ventricle congenital heart defects: a prospective randomized study. J Intensive Care. 2022. PMID: 36229863. doi:10.1186/s40560-022-00639-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。